Navigation Links
Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
Date:8/27/2008

Patients may need to be on telmisartan longer to see positive effect, researchers say

WEDNESDAY, Aug. 27 (HealthDay News) -- The blood pressure drug telmisartan does not lower the rate of stroke, cardiovascular events or diabetes better than a placebo in patients who have had a stroke, a new study finds.

Telmisartan is an angiotensin II receptor blocker, which works by blocking the action of chemicals that constrict the blood vessels enabling the blood to flow more smoothly, thus lowering blood pressure.

"Overall, there was no difference in the two groups, people taking telmisartan and those taking placebo," said study co-researcher Dr. Ralph L. Sacco, chairman of neurology at the University of Miami's Miller School of Medicine. "However, we did find a difference in that those who were in the study longer the drug had an effect compared to those who were in the study for a short time."

Sacco thinks that the longer someone takes telmisartan may increase its effectiveness in preventing additional strokes. "These effects have not been seen early after a stroke, they may be more delayed," he said. "The follow-up time in this study was only two a half years, and it may have hurt us."

Blood pressure control is essential in preventing strokes, Sacco said. "But this study in itself doesn't say you have to use angiotensin II receptor blocker early," he said. "Other studies have suggested that these drugs may be better for stroke risk reduction, but in this study, we can't say that."

The report was released early in the Aug. 27 issue of the New England Journal of Medicine.

For the study, Sacco's group randomly assigned 20,332 stroke patients to daily doses of telmisartan or placebo. The researchers looked for incidents of stroke in cardiovascular events such as heart attack and heart failure. They also looked for new cases of diabetes.

Over two-and-a-half years of follow-up, 8.7 percent of patients receiving telmisartan suffered a stroke, compared with 9.2 percent of the patients receiving placebo. In addition, 13.5 percent of patients taking telmisartan had a major cardiovascular event versus 14.4 percent of patients in the placebo group. Diabetes occurred in 1.7 percent of patients taking telmisartan and in 2.1 percent of patients receiving placebo.

In a second study in the same issue of the journal, researchers led by Sacco compared the effectiveness of two drug regimens designed to reduce clotting, Persantine (Dipyridamole) plus aspirin or Plavix (clopidogrel) in preventing new strokes among the same group of patients as in the first study.

"The two drugs were essentially the same in terms of their ability to reduce the risk of recurrent stroke, as well as reducing the risk of heart attack and death after a stroke," Sacco said.

During two-and-a-half years of follow-up, 9 percent of the patients taking Persantine and aspirin suffered a stroke compared with 8.8 percent of those taking Plavix. In both groups, 13.1 percent of the patients had a heart attack or died.

"Both drugs are equally effective; neither drug is superior to the other in terms of reducing a recurrent stroke," Sacco said.

Deciding which drug regimen to use depends on the individual patient, Sacco said. "In some patients, we may use Plavix, particularly in those who have cardiac disease, and in some patients, we may still use this combination of Persantine and aspirin. Choices are helpful, since different people respond differently to different medicines," he said.

More information

For more on stroke, visit the American Stroke Association.



SOURCES: Ralph L. Sacco, M.D., chairman, neurology, Miller School of Medicine, University of Miami; Aug. 27, 2008, New England Journal of Medicine online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer antidepressants led to less, not more, teen suicides
2. Newer Antibiotic Speeds TB Healing
3. Newer radiation treatment easier for some throat cancer patients
4. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
5. Newer Sedative Might Help Patients on Ventilators
6. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
7. Newer Prostate Cancer Treatment Similar to Traditional Surgery
8. Specific antagonism lowers blood pressure
9. Restricting Blood Flow May Help Heart Bypass Patients
10. FDA Updates Prescription Guidelines for Blood Thinner
11. Doctors Often Miss High Blood Pressure in Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved ... join her with one on her shoulder and one on her arm. But she ... because of years of mitral valve prolapse. , The valves of the heart wouldn’t ...
(Date:5/3/2016)... ... May 03, 2016 , ... University of the People, ... launch of its Associates and Bachelor's degrees in Health Studies. Leading figures are ... Dr. Torsten N. Wiesel; Chairman and CEO of Fortune 500® company Henry Schein, ...
(Date:5/3/2016)... ... ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) Center — ... procedures in an environment that looks and feels real. , Located in the heart ... “hackers” to develop and test new devices or software platforms and see how they ...
(Date:5/3/2016)... ... ... Park Cities Pet Sitter has openings for both full-time and part-time ... 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These zip codes ... and Park Cities areas of the Metroplex. Candidates must love animals, have attention ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... industry, announced today that Legacy Health is expanding its use of Intrigma’s cloud-based ... a highly successful initial proof of concept. The Portland, Oregon based health system ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
Breaking Medicine Technology: